Michelle A. Petri

Michelle A. Petri's AcademicInfluence.com Rankings

Michelle A. Petri

Engineering

#1619

World Rank

#2350

Historical Rank

Bioengineering

World Rank

Historical Rank

Biomedical Engineering

#33

World Rank

#33

Historical Rank

Applied Physics

#139

World Rank

#148

Historical Rank

engineering Degrees

Michelle A. Petri

Biology

#3128

World Rank

#4825

Historical Rank

Cell Biology

#64

World Rank

#68

Historical Rank

Molecular Biology

#209

World Rank

#213

Historical Rank

Genetics

#222

World Rank

#269

Historical Rank

biology Degrees

Download Badge

Engineering
Biology

Michelle A. Petri's Degrees

Masters Biochemistry Stanford University

Why Is Michelle A. Petri Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michelle A. Petri's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. (2011) (3649)
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. (1996) (2101)
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. (1999) (1841)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial (2011) (1507)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. (2011) (1208)
Combined Oral Contraceptives in Women With Systemic Lupus Erythematosus (2005) (958)
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. (2008) (926)
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus (2009) (782)
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. (1997) (691)
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. (2004) (689)
A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus (2006) (680)
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. (2005) (673)
Risk factors for coronary artery disease in patients with systemic lupus erythematosus. (1992) (641)
Mortality in systemic lupus erythematosus. (1987) (584)
The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial (2005) (577)
Anti-inflammatory and immunosuppressive drugs and reproduction (2006) (548)
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. (2009) (540)
Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. (1996) (483)
Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. (1998) (481)
Distinct Effector B Cells Induced by Unregulated Toll‐like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus (2018) (473)
Hydroxychloroquine in lupus pregnancy. (2006) (458)
Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus (2007) (454)
Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus (2008) (447)
Damage in systemic lupus erythematosus and its association with corticosteroids. (2000) (441)
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. (2000) (440)
Epidemiology of the antiphospholipid antibody syndrome. (2000) (439)
Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus (1996) (423)
Novel evidence-based systemic lupus erythematosus responder index. (2009) (412)
Catastrophic Antiphospholipid Syndrome: Clues to the Pathogenesis from a Series of 80 Patients (2001) (404)
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. (2008) (395)
Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. (2010) (386)
The impact of increased lupus activity on obstetric outcomes. (2005) (385)
Management of thrombosis in antiphospholipid antibody syndrome. (2001) (384)
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2014) (377)
An international cohort study of cancer in systemic lupus erythematosus. (2005) (372)
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. (2007) (369)
The immune cell landscape in kidneys of patients with lupus nephritis (2019) (369)
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies (2009) (356)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response (2012) (347)
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials (2012) (340)
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. (1994) (338)
Human polymorphism at microRNAs and microRNA target sites. (2013) (330)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (2018) (325)
Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. (2008) (324)
Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. (1991) (316)
Predictors of Survival in Systemic Lupus Erythematosus (2006) (313)
Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. (2012) (311)
Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. (2004) (303)
The frequency and outcome of lupus nephritis: results from an international inception cohort study. (2016) (301)
Systemic lupus erythematosus: Diagnosis and clinical management. (2019) (289)
Elevated Serum Levels of Interferon-Regulated Chemokines Are Biomarkers for Active Human Systemic Lupus Erythematosus (2006) (286)
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. (2007) (285)
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study (2013) (280)
Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. (1999) (279)
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus (2011) (267)
Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. (2009) (267)
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) (2016) (259)
Transancestral mapping and genetic load in systemic lupus erythematosus (2017) (253)
Coronary Artery Disease Risk Factors in the Johns Hopkins Lupus Cohort: Prevalence, Recognition by Patients, and Preventive Practices (1992) (252)
Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study (2013) (250)
Cancer risk in systemic lupus: an updated international multi-centre cohort study. (2013) (242)
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study (2011) (241)
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus (2009) (236)
Immunoablative High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory, Severe Autoimmune Disease (1998) (236)
Classification and definition of major flares in SLE clinical trials (1999) (233)
Fatal Infections in Systemic Lupus Erythematosus: The Role of Opportunistic Organisms (1987) (233)
Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort (2011) (231)
Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. (2005) (231)
The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. (1987) (231)
Management strategies and future directions for systemic lupus erythematosus in adults (2019) (230)
Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. (2012) (228)
Baseline characteristics of a multiethnic lupus cohort: PROFILE (2002) (227)
End‐Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1 (2014) (226)
Predictors of Pregnancy Outcomes in Patients With Lupus (2015) (225)
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. (2014) (224)
Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. (1992) (220)
Epidemiology of systemic lupus erythematosus. (2002) (217)
Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort (2000) (214)
Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. (2012) (212)
Lupus Atherosclerosis Prevention Study (LAPS) (2010) (210)
Validity and reliability of lupus activity measures in the routine clinic setting. (1992) (209)
Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus (2008) (207)
Differential Genetic Associations for Systemic Lupus Erythematosus Based on Anti–dsDNA Autoantibody Production (2011) (205)
Biochemical characterization of ADP-ribose polymer metabolism in SLE. (1996) (205)
Risk factors for osteonecrosis in systemic lupus erythematosus. (1997) (203)
Epidemiology of systemic lupus erythematosus: an update (2017) (198)
Association of Genetic Variants in Complement Factor H and Factor H-Related Genes with Systemic Lupus Erythematosus Susceptibility (2011) (193)
Percutaneous vertebroplasty treatment of steroid-induced osteoporotic compression fractures. (1998) (192)
Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients (1997) (191)
Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. (2001) (190)
Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. (1995) (187)
Prednisone, Lupus Activity, and Permanent Organ Damage (2009) (186)
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study (2015) (183)
Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. (2002) (183)
Outcome measures to be used in clinical trials in systemic lupus erythematosus. (1999) (182)
Managing lupus patients during pregnancy. (2013) (181)
Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus (2009) (179)
Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. (1996) (179)
A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. (2001) (178)
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. (2008) (177)
Assessing disease activity in SLE patients during pregnancy (1999) (176)
Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. (1996) (173)
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis (2006) (173)
Patterns of disease activity in systemic lupus erythematosus. (1999) (172)
Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive Patients (2011) (170)
Systemic lupus erythematosus one disease or many? (2012) (170)
Distinct subtypes of myelitis in systemic lupus erythematosus. (2009) (169)
Procoagulants and osteonecrosis. (2003) (169)
Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women. (1987) (168)
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus (2010) (167)
Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. (1993) (167)
Assessment of systemic lupus erythematosus. (2005) (167)
Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. (2010) (166)
Risk Alleles for Systemic Lupus Erythematosus in a Large Case-Control Collection and Associations with Clinical Subphenotypes (2011) (165)
The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. (2015) (164)
A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. (1997) (164)
Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? (2005) (163)
Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. (2012) (159)
Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus (2009) (159)
Early Risk Factors for Pregnancy Loss in Lupus (2006) (157)
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. (1996) (156)
Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus (2014) (155)
Morbidity of systemic lupus erythematosus: role of race and socioeconomic status (1992) (153)
Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. (2002) (152)
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study (2014) (152)
Randomized, double-blind, placebo-controlled study of the treatment of the painful shoulder. (1987) (152)
Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. (2013) (152)
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case–cohort study (2007) (151)
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. (2013) (151)
Differences between Male and Female Systemic Lupus Erythematosus in a Multiethnic Population (2012) (150)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials (2016) (149)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials (2016) (149)
International consensus for a definition of disease flare in lupus (2011) (149)
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. (2004) (149)
An update on mortality in systemic lupus erythematosus. (2008) (145)
High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. (2003) (145)
Pulmonary hypertension in systemic lupus erythematosus. (1989) (140)
Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus (2011) (138)
Measurement of fatigue in systemic lupus erythematosus: a systematic review. (2007) (138)
Unmet medical needs in systemic lupus erythematosus (2012) (137)
Sex hormones and systemic lupus erythematosus (2008) (136)
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort (2012) (135)
The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. (2004) (135)
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus (2011) (135)
Review of classification criteria for systemic lupus erythematosus. (2005) (135)
Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. (1991) (134)
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study (2012) (132)
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence (2015) (131)
Oral contraceptives and systemic lupus erythematosus. (1997) (130)
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials (2013) (128)
Endpoints: consensus recommendations from OMERACT IV (2000) (126)
Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis (2016) (125)
Hopkins Lupus Pregnancy Center: 1987 to 1996. (1997) (122)
A polymorphism within IL21R confers risk for systemic lupus erythematosus. (2009) (121)
Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report (2003) (120)
Pregnancy and reproduction in autoimmune rheumatic diseases. (2011) (120)
The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. (2004) (119)
Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. (2011) (119)
Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis (2009) (118)
Hopkins Lupus Cohort. 1999 update. (2000) (118)
PD-1hi CXCR5- T peripheral helper cells promote B cells responses in lupus via MAF and IL-21. (2019) (118)
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus (2011) (117)
Pathogenesis and treatment of the antiphospholipid antibody syndrome. (1997) (116)
Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. (2012) (116)
IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. (2012) (115)
Clinical features of systemic lupus erythematosus (1994) (114)
Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort (2015) (113)
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. (2013) (113)
‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010 (2011) (113)
One Hundred Anti‐Ro (SS‐A) Antibody Positive Patients: A 10‐Year Follow‐Up (1995) (112)
Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. (2012) (112)
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. (2016) (112)
Self-reactive IgE exacerbates interferon responses associated with autoimmunity (2015) (112)
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort (2012) (111)
Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus (2013) (111)
The SLE Transcriptome Exhibits Evidence of Chronic Endotoxin Exposure and Has Widespread Dysregulation of Non-Coding and Coding RNAs (2014) (111)
The Hopkins Lupus Pregnancy Center: ten key issues in management. (2007) (109)
Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. (2019) (108)
The rate and pattern of organ damage in late onset systemic lupus erythematosus. (2002) (108)
The Clinical Utility of Measuring Complement and Anti-dsDNA Antibodies During Pregnancy in Patients with Systemic Lupus Erythematosus (2011) (107)
Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers (2011) (107)
Renal biopsy in lupus patients with low levels of proteinuria. (2007) (107)
The Fc gamma RIIIA-158F allele is a risk factor for systemic lupus erythematosus (1998) (107)
Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results (2016) (107)
Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. (1999) (106)
Effect of pregnancy on disease flares in patients with systemic lupus erythematosus (2018) (106)
Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. (2014) (106)
Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. (2010) (105)
Depression and Cognitive Impairment in Newly Diagnosed Systemic Lupus Erythematosus (2010) (105)
Lymphoma risk in systemic lupus: effects of disease activity versus treatment (2012) (105)
Admixture Mapping in Lupus Identifies Multiple Functional Variants within IFIH1 Associated with Apoptosis, Inflammation, and Autoantibody Production (2013) (105)
Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity (2011) (103)
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort (2018) (103)
Anti-C1q antibodies in systemic lupus erythematosus (2015) (103)
Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans (2008) (102)
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. (2008) (102)
Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. (2011) (101)
Two Major Autoantibody Clusters in Systemic Lupus Erythematosus (2012) (101)
Peripheral Neuropathies in Systemic Lupus Erythematosus: Clinical Features, Disease Associations, and Immunologic Characteristics Evaluated Over a Twenty‐Five–Year Study Period (2014) (101)
Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. (2013) (100)
Infection in systemic lupus erythematosus. (1998) (100)
Update on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort (2010) (99)
MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus (2013) (99)
Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies (2018) (98)
Fibromyalgia, Systemic Lupus Erythematosus (SLE), and Evaluation of SLE Activity (2008) (98)
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA (2010) (97)
Cyclophosphamide for lupus during pregnancy (2005) (97)
Antibiotic allergy in systemic lupus erythematosus: a case-control study. (1992) (96)
Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups (2012) (95)
Effect of eicosapentaenoic acid in asthma (1988) (94)
Time to Renal Disease and End-Stage Renal Disease in PROFILE: A Multiethnic Lupus Cohort (2006) (94)
Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. (1988) (93)
Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. (2006) (93)
Predictors of carotid atherosclerosis in systemic lupus erythematosus. (2006) (93)
Immunosuppressive Drug Use in Pregnancy (2003) (90)
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial (2016) (90)
Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. (2008) (90)
Analysis of autosomal genes reveals gene–sex interactions and higher total genetic risk in men with systemic lupus erythematosus (2011) (89)
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. (2011) (89)
High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. (2009) (88)
Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. (2011) (88)
Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2014) (87)
Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort (2007) (87)
Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group. (1996) (86)
Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. (2004) (86)
Cytosolic 5′‐Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases (2015) (86)
ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry (2009) (84)
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. (2013) (84)
Correlation of serum measures of nitric oxide production with lupus disease activity. (1999) (84)
Management of pregnancy in systemic lupus erythematosus (2012) (83)
Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. (2008) (83)
Cyclophosphamide: new approaches for systemic lupus erythematosus (2004) (82)
Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. (2012) (81)
An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus (2002) (81)
Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. (2000) (81)
Genetic associations of LYN with systemic lupus erythematosus (2009) (81)
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. (2009) (80)
SLE patients with renal damage incur higher health care costs. (2007) (79)
Remission in systemic lupus erythematosus: durable remission is rare (2016) (79)
Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. (2011) (78)
Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices (2015) (77)
Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy (2020) (77)
Association of IgA Anti-ß2 Glycoprotein I with Clinical and Laboratory Manifestations of Systemic Lupus Erythematosus (2011) (77)
Insulin Resistance in Rheumatoid Arthritis: Disease‐Related Indicators and Associations With the Presence and Progression of Subclinical Atherosclerosis (2015) (76)
The lupus family registry and repository. (2011) (75)
Interferon‐alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses (2010) (75)
Evaluation of Preterm Delivery in a Systemic Lupus Erythematosus Pregnancy Clinic (1995) (74)
Atraumatic osteonecrosis of the humeral head. (2000) (74)
Brain Magnetic Resonance Imaging in Newly Diagnosed Systemic Lupus Erythematosus (2008) (74)
Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis. (1990) (74)
Clinical Expression of Systemic Lupus Erythematosus in Patients with C4A Deficiency (1993) (72)
Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. (2012) (72)
Stratification of Systemic Lupus Erythematosus Patients Into Three Groups of Disease Activity Progression According to Longitudinal Gene Expression (2018) (72)
Genetic variation in the CRP promoter: association with systemic lupus erythematosus. (2008) (72)
Immunomodulators in SLE: Clinical evidence and immunologic actions. (2016) (72)
Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjögren's syndrome. (1994) (71)
Global H4 acetylation analysis by ChIP-chip in SLE monocytes (2009) (71)
ABIN1 dysfunction as a genetic basis for lupus nephritis. (2013) (70)
Serial assessment of glomerular filtration rate in lupus nephropathy. (1988) (70)
Kidney biopsy in lupus nephritis: look before you leap. (2006) (70)
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. (2008) (70)
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort (2014) (69)
Pancreatitis in Systemic Lupus Erythematosus: Frequency and Associated Factors — A Review of the Hopkins Lupus Cohort (2010) (69)
Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue (2018) (69)
Malignant Diseases and Mortality Rate (1985) (68)
Increased Prevalence of Carotid Artery Atherosclerosis in Rheumatoid Arthritis Is Artery-specific (2010) (67)
The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. (2007) (67)
Prevalence of Flare and Influence of Demographic and Serologic Factors on Flare Risk in Systemic Lupus Erythematosus: A Prospective Study (2009) (67)
Secondary Sjögren’s Syndrome in Systemic Lupus Erythematosus Defines a Distinct Disease Subset (2010) (67)
Discoid lupus erythematosus‐like lesions and stomatitis in female carriers of X‐linked chronic granulomatous disease (1981) (67)
The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. (2004) (67)
Classification criteria for systemic lupus erythematosus: a review (2004) (67)
The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. (2001) (67)
Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort (2019) (67)
The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. (2014) (67)
Biologics in the treatment of systemic lupus erythematosus (2010) (66)
Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis (2009) (66)
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus (2019) (66)
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006 (2013) (66)
Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus. (1997) (66)
Prevalence of a mutation causing C2 deficiency in systemic lupus erythematosus. (1994) (66)
Epidemiology of Antiphospholipid Syndrome (2006) (66)
Can Women with Systemic Lupus Erythematosus Safely Use Exogenous Estrogens? (1995) (66)
An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. (1999) (65)
The Hopkins Lupus Pregnancy Center: 1987–1991 Update (1992) (65)
Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis (2012) (65)
High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. (2008) (65)
Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity (2013) (64)
Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. (2003) (63)
25‐Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort (2014) (63)
Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. (2012) (63)
Autoantibody tests in autoimmune thyroid disease: a case-control study. (1991) (63)
Cognitive function in a systemic lupus erythematosus inception cohort. (2008) (63)
The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics Classification criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary (2014) (63)
The TNFα locus is altered in monocytes from patients with systemic lupus erythematosus (2007) (63)
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials (2014) (63)
Thyroid disease in pregnant women with systemic lupus erythematosus: increased preterm delivery (2011) (63)
Prospective study of systemic lupus erythematosus pregnancies (2004) (62)
Disease activity assessment in SLE: do we have the right instruments? (2007) (62)
Quality-of-Life Measurements Versus Disease Activity in Systemic Lupus Erythematosus (2010) (62)
Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. (2017) (61)
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis (1996) (61)
Lupus in Baltimore: evidence-based ‘clinical pearls’ from the Hopkins Lupus Cohort (2005) (61)
Hormone replacement and contraceptive therapy in autoimmune diseases. (2012) (60)
Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. (2008) (60)
Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. (2014) (60)
Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis (2010) (60)
Systemic Lupus Erythematosus and Pregnancy. (2017) (60)
The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. (2000) (59)
PTPN22 Association in Systemic Lupus Erythematosus (SLE) with Respect to Individual Ancestry and Clinical Sub-Phenotypes (2013) (58)
T helper cell dysfunction in systemic lupus erythematosus (SLE): Relation to disease activity (1994) (58)
Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort (2015) (57)
Hair product use in systemic lupus erythematosus. A case-control study. (1992) (57)
Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. (2000) (57)
European genetic ancestry is associated with a decreased risk of lupus nephritis. (2012) (57)
Allelic-Dependent Expression of an Activating Fc Receptor on B Cells Enhances Humoral Immune Responses (2013) (57)
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. (2019) (57)
Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis (2011) (57)
Variation in the ICAM1–ICAM4–ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries (2012) (57)
The Role of Genetic Variation Near Interferon-Kappa in Systemic Lupus Erythematosus (2010) (56)
Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. (2004) (56)
2013 Update: Hopkins Lupus Cohort (2013) (55)
Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort (2016) (55)
Management of antiphospholipid syndrome in pregnancy. (2006) (54)
Diagnosis of antiphospholipid antibodies. (1994) (54)
Fine-mapping and transethnic genotyping establish IL2/IL21 genetic association with lupus and localize this genetic effect to IL21. (2011) (54)
A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus (2012) (54)
The Histologic Spectrum of Prepuces from Patients with Phimosis (1988) (53)
2021 DORIS definition of remission in SLE: final recommendations from an international task force (2021) (53)
Predictors of self-reported health-related quality of life in systemic lupus erythematosus. (2013) (53)
Genetic analyses of interferon pathway-related genes reveal multiple new loci associated with systemic lupus erythematosus. (2011) (53)
Lung cancer in systemic lupus erythematosus. (2007) (52)
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus (2011) (51)
Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis. (2004) (51)
Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus (2015) (51)
Evaluation of TRAF6 in a large multiancestral lupus cohort. (2012) (51)
Lupus and Pregnancy (1995) (51)
A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. (2009) (51)
Mononeuritis Multiplex: The Yield of Evaluations for Occult Rheumatic Diseases (1988) (51)
Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy (2016) (50)
Femoral head perfusion and composition: MR imaging and spectroscopic evaluation of patients with systemic lupus erythematosus and at risk for avascular necrosis. (1995) (50)
Neonatal lupus erythematosus. Report of serological and immunogenetic studies in twins discordant for congenital heart block (1994) (50)
Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. (2011) (50)
Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. (2011) (50)
The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being. (2005) (50)
Urinary Vascular Cell Adhesion Molecule, But Not Neutrophil Gelatinase-associated Lipocalin, Is Associated with Lupus Nephritis (2012) (50)
Predictors of Incident Depression in Systemic Lupus Erythematosus (2014) (49)
Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population (2009) (49)
IgM Anti-ß2 Glycoprotein I Is Protective Against Lupus Nephritis and Renal Damage in Systemic Lupus Erythematosus (2011) (49)
Race/ethnicity and cancer occurrence in systemic lupus erythematosus. (2005) (49)
Longitudinal analysis of peripheral blood T cell receptor diversity in patients with systemic lupus erythematosus by next-generation sequencing (2015) (48)
Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study. (2016) (48)
Review : Antiphospholipid antibodies and retinal vascular disease (1996) (48)
Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus (2019) (48)
Development and initial validation of a self‐assessed lupus organ damage instrument (2010) (47)
The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. (1998) (47)
Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares. (2006) (47)
Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort (2015) (47)
"Subcortical" cognitive impairment in patients with systemic lupus erythematosus. (2000) (46)
Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials (2016) (46)
Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis (2011) (46)
Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self‐Administered Questionnaires (2018) (46)
Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus (2014) (46)
High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. (2010) (45)
Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2018) (45)
Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort (2017) (45)
5 Pregnancy in SLE (1998) (45)
Factors Associated with Arterial Vascular Events in PROFILE: A Multiethnic Lupus Cohort (2009) (44)
Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression (2013) (44)
Decreased live births in women with systemic lupus erythematosus (2011) (44)
The effect of race on incidence and clinical course in systemic lupus erythematosus: The Hopkins Lupus Cohort. (1998) (43)
The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients (2017) (43)
Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities (2020) (43)
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. (2008) (43)
Anti-Ro antibodies and neonatal lupus. (1989) (43)
Atherosclerosis in Systemic Lupus Erythematosus (2013) (42)
Utility of Antiphosphatidylserine/Prothrombin and IgA Antiphospholipid Assays in Systemic Lupus Erythematosus (2013) (42)
Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus (2013) (42)
Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy (2019) (41)
A quantitative lateral flow assay to detect complement activation in blood. (2015) (41)
C4A deficiency due to a 2 bp insertion is increased in patients with systemic lupus erythematosus. (1999) (41)
Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus (2018) (41)
Abnormal Production of Pro- and Anti-Inflammatory Cytokines by Lupus Monocytes in Response to Apoptotic Cells (2011) (40)
Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years (2012) (40)
Associates and predictors of pleurisy or pericarditis in SLE (2017) (40)
Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. (2011) (40)
Interferon-γ polymorphisms in systemic lupus erythematosus (2001) (40)
Lymphotoxin-LIGHT Pathway Regulates the Interferon Signature in Rheumatoid Arthritis (2014) (40)
The Role of MicroRNAs and Human Epidermal Growth Factor Receptor 2 in Proliferative Lupus Nephritis (2015) (40)
Wegener's granulomatosis: isolated involvement of the trachea and larynx. (1987) (39)
Long‐Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate‐to‐ Severe Systemic Lupus Erythematosus: Results From an Open‐Label Extension Study (2016) (39)
Clinical features of systemic lupus erythematosus (1993) (39)
Disassociation of sex hormone levels and cytokine production in SLE patients (2001) (39)
Frequency of the Fc gamma RIIIA-158F allele in African American patients with systemic lupus erythematosus. (1999) (39)
Interferon regulatory factor 1 and histone H4 acetylation in systemic lupus erythematosus (2015) (39)
Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss (2015) (38)
Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2019) (38)
Neuropsychological Functioning and Its Relationship to Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus (2002) (38)
Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases (2008) (38)
Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. (2015) (38)
Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy (2001) (38)
Seasonal Variation in the Activity of Systemic Lupus Erythematosus (2012) (37)
Development of Biomarker Models to Predict Outcomes in Lupus Nephritis (2016) (37)
Development of a systemic lupus erythematosus cardiovascular risk equation (2019) (37)
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort (2018) (36)
Pregnancy and Systemic Lupus Erythematosus. (2019) (36)
Fcγ Receptor IIIa Single‐Nucleotide Polymorphisms and Haplotypes Affect Human IgG Binding and Are Associated With Lupus Nephritis in African Americans (2014) (36)
Classification and Epidemiology of the Antiphospholipid Syndrome (2002) (36)
Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis. (2015) (35)
Low frequency of flares during pregnancy and post-partum in stable lupus patients (2020) (35)
Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines (2018) (35)
Integrated urine proteomics and renal single-cell genomics identify an interferon-γ response gradient in lupus nephritis. (2020) (35)
Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus. (2013) (35)
Socioeconomic status in systemic lupus erythematosus (2006) (35)
Association of Antibodies to Interferon‐Inducible Protein‐16 With Markers of More Severe Disease in Primary Sjögren's Syndrome (2016) (35)
BELIMUMAB, A BLYS-SPECIFIC INHIBITOR, REDUCES DISEASE ACTIVITY AND SEVERE FLARES IN SEROPOSITIVE SLE PATIENTS (2011) (35)
Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans (2018) (35)
Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort (2012) (35)
Treatment of systemic lupus erythematosus: an update. (1998) (35)
PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome (2015) (34)
Hydroxychloroquine: past, present, future (1998) (34)
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab (2017) (34)
High-Dose Cyclophosphamide Without Stem Cell Rescue in 207 Patients With Aplastic Anemia and Other Autoimmune Diseases (2011) (34)
Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes (2019) (34)
The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository (2019) (34)
Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. (2006) (34)
Anti-C1q in systemic lupus erythematosus (2016) (33)
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study (2020) (33)
Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. (2007) (32)
Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod (2017) (32)
Prevention and management of co-morbidities in SLE. (2014) (32)
A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach (2016) (32)
Noncalcified Coronary Plaque in Systemic Lupus Erythematosus (2010) (32)
Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort (2013) (32)
Risk factors for cataracts in systemic lupus erythematosus (SLE) (2015) (31)
Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel (2014) (31)
Lupus risk variants in the PXK locus alter B-cell receptor internalization (2015) (31)
Lupus enteritis: an uncommon manifestation of systemic lupus erythematosus. (2013) (31)
Progression of coronary artery atherosclerosis in rheumatoid arthritis: comparison with participants from the Multi-Ethnic Study of Atherosclerosis (2013) (31)
H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus (2016) (31)
Transient ischemic attack and stroke in systemic lupus erythematosus (2013) (31)
The clinical syndrome associated with antiphospholipid antibodies. (1992) (31)
Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus (2019) (30)
Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus (2013) (30)
Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE (2019) (30)
3′ polymorphisms of ETS1 are associated with different clinical phenotypes in SLE (2000) (30)
Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus (2008) (30)
Overlap of granulomatous vasculitis and sarcoidosis: presentation with uveitis, eosinophilia, leg ulcers, sinusitis, and past foot drop. (1988) (30)
European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. (2009) (30)
Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis (2018) (29)
Effect of pregnancy on serum cytokines in SLE patients (2012) (29)
Estimating renal function in lupus nephritis: comparison of the Modification of Diet in Renal Disease and Cockcroft—Gault equations (2007) (29)
Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus (2020) (29)
The automated modified Russell viper venom time test for the lupus anticoagulant. (1991) (29)
Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing (2009) (29)
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus (2018) (29)
Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease. (1994) (29)
Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus (2018) (28)
American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort (2014) (28)
Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis. (2008) (28)
Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes (2016) (28)
Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis (2020) (28)
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways (2020) (28)
Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort experience. (1999) (27)
Breast Cancer in Systemic Lupus Erythematosus (2013) (27)
Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach (2020) (27)
Interferon-gamma polymorphisms in systemic lupus erythematosus. (2001) (27)
Association of coping responses with fibromyalgia tender points in patients with systemic lupus erythematosus. (2000) (27)
Renal biopsy in the management of lupus nephritis during pregnancy (2015) (27)
Systemic Lupus Erythematosus: 2006 Update (2006) (27)
Gene Expression and Pharmacodynamic‐Induced Changes in 1,760 SLE Patients from Two Phase III Trials of B Cell Activating Factor Blockade with Tabalumab (2016) (26)
Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing (2009) (26)
Multiplex giant magnetoresistive biosensor microarrays identify interferon-associated autoantibodies in systemic lupus erythematosus (2016) (26)
Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus (2019) (26)
The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus. (2007) (26)
Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE (2016) (26)
Pericarditis in Lupus (2019) (26)
A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self‐Administered Questionnaires (2018) (26)
Pancreatitis in systemic lupus erythematosus: still in search of a mechanism. (1992) (26)
Monocyte enhancers are highly altered in systemic lupus erythematosus. (2015) (26)
Interferon Regulatory Factor 1 Marks Activated Genes and Can Induce Target Gene Expression in Systemic Lupus Erythematosus (2015) (26)
Impaired Health Status and the Effect of Pain and Fatigue on Functioning in Clinical Trial Patients with Systemic Lupus Erythematosus (2013) (26)
Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification (2019) (26)
Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study (2018) (26)
Comparison of different methods of classifying patients with systemic lupus erythematosus. (1991) (26)
The Risk Benefit Ratio of Glucocorticoids in SLE: Have Things Changed over the Past 40 years? (2017) (25)
Elevation of maternal alpha-fetoprotein in systemic lupus erythematosus: a controlled study. (1995) (24)
Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages (2020) (24)
Long-term outcomes in lupus. (2001) (24)
Genetic Risk Factors for Thrombosis in Systemic Lupus Erythematosus (2012) (24)
Low Socioeconomic Status Is Associated with Cardiovascular Risk Factors and Outcomes in Systemic Lupus Erythematosus (2012) (24)
Pregnancy in SLE. (1998) (24)
Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients (2017) (24)
Dermatologic lupus: Hopkins Lupus Cohort. (1998) (24)
Classification criteria for antiphospholipid syndrome: the case for cardiac valvular disease. (2004) (23)
Dyspnea in ambulatory patients with SLE: prevalence, severity, and correlation with incremental exercise testing. (1995) (23)
Predictors of Incident Seizure in Systemic Lupus Erythematosus (2016) (23)
Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus. (2016) (23)
Monitoring systemic lupus erythematosus in standard clinical care. (2007) (22)
Neonatal Lupus Erythematosus Syndrome: Analysis of C4 Allotypes and C4 Genes in 18 Failies (1992) (22)
Breast cancer in systemic lupus (2017) (22)
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. (2020) (22)
A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus (2018) (22)
Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. (2008) (22)
High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures (2008) (22)
Effi cacy and safety of belimumab in patients with active systemic lupus erythematosus : a randomised , placebo-controlled , phase 3 trial (2011) (21)
Why targeted therapies are necessary for systemic lupus erythematosus (2016) (21)
Equivalence trials in SLE research: issues to consider (1999) (21)
Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [11C]DPA-713 positron emission tomography (2017) (21)
The Non-Muscle Myosin Heavy Chain 9 Gene (MYH9) Is Not Associated with Lupus Nephritis in African Americans (2010) (21)
Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. (2020) (21)
Serum complement determinations in patients with quiescent systemic lupus erythematosus. (1996) (21)
Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index (2020) (21)
BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year (2015) (21)
Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis (2018) (20)
Antiphospholipid Syndrome. (2020) (20)
Neuropsychiatric systemic lupus erythematosus (2003) (20)
Clinical associations of proinflammatory cytokines, oxidative biomarkers and vitamin D levels in systemic lupus erythematosus (2017) (20)
Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort (2018) (20)
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort (2021) (20)
Predictors of predominant Lupus Low Disease Activity State (LLDAS-50) (2019) (20)
Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study (2015) (20)
The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA (2016) (20)
European population substructure correlates with systemic lupus erythematosus endophenotypes in North Americans of European descent (2010) (20)
SLE-key(®) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP(®). (2016) (20)
Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus (2015) (19)
Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort (2008) (19)
Neurally mediated hypotension in systemic lupus erythematosus patients with fibromyalgia. (2004) (19)
Large intracranial arteritis with giant cells in systemic lupus erythematosus. (1986) (19)
Semiquantified Noncalcified Coronary Plaque in Systemic Lupus Erythematosus (2012) (19)
Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. (2008) (19)
Prevalence of cerebral microemboli in systemic lupus erythematosus: transcranial Doppler. (2001) (19)
Number of fibromyalgia tender points is associated with health status in patients with systemic lupus erythematosus. (2005) (18)
High-dose cyclophosphamide and stem cell transplantation for refractory systemic lupus erythematosus. (2006) (18)
Diet and systemic lupus erythematosus: from mouse and monkey to woman? (2001) (18)
A Polymorphism in TLR2 Is Associated With Arterial Thrombosis in a Multiethnic Population of Patients With Systemic Lupus Erythematosus (2014) (18)
Systemic lupus erythematosus and pregnancy. (1994) (18)
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus (2021) (18)
Oral candidiasis in systemic lupus erythematosus (2014) (18)
Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach (2018) (18)
Efficacy and safety of epratuzumab in patients with moderate / severe active systemic lupus erythematosus : results from EMBLEM , a phase (2013) (18)
Progression of noncalcified and calcified coronary plaque by CT angiography in SLE (2016) (18)
Fatigue Measurements in Systemic Lupus Erythematosus (2019) (17)
Predictors of incident proteinuria among patients with SLE (2017) (17)
Specificity of the STAT 4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus (2008) (17)
Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry (2020) (17)
Diffuse lymphadenopathy as the presenting manifestation of systemic lupus erythematosus. (2013) (17)
Digital necrosis: a paraneoplastic syndrome. (1985) (17)
Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment (2018) (17)
Epidemiology of the Antiphospholipid Syndrome (2017) (17)
T FcRIIIA158F allele is a risk factor for systemic lupus erythematosus (1998) (16)
Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America (2019) (16)
Lupus and pregnancy. (2011) (16)
COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) (2021) (16)
Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE (2018) (16)
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index (2018) (16)
Apolipoprotein‐Containing Lipoprotein Subclasses and Subclinical Atherosclerosis in Systemic Lupus Erythematosus (2015) (15)
An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort. (2015) (15)
Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity (2020) (15)
Hydroxychloroquine-Induced Erythema Multiforme. (2017) (15)
A Spatiotemporal Analysis of Organ‐Specific Lupus Flares in Relation to Atmospheric Variables and Fine Particulate Matter Pollution (2020) (15)
Hematopoietic stem cell transplantation for systemic lupus erythematosus. (2000) (15)
Aortic valve calcification in systemic lupus erythematosus (2006) (15)
SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus (2019) (15)
Systemic lupus erythematosus: women's health issues. (2000) (14)
Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production (2016) (14)
Laryngeal infection in lupus: report of nocardiosis and review of laryngeal involvement in lupus. (1988) (14)
Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus (2017) (14)
Healthcare costs of pregnancy in systemic lupus erythematosus: retrospective observational analysis from a US health claims database (2015) (14)
A Cytolytic Parasite in the Cells of Transplantable, Malignant Tumours (1965) (14)
Brief Report: Single-nucleotide polymorphisms in VKORC1 are risk factors for systemic lupus erythematosus in Asians. (2013) (14)
Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA (2014) (14)
Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort (2018) (14)
High-Resolution Analysis of Antibodies to Post-Translational Modifications Using Peptide Nanosensor Microarrays. (2016) (14)
OP0041 Pregnancy Outcomes for Systemic Lupus Erythematosus (SLE) Subjects with Conception during Belimumab Intravenous (IV) and Subcutaneous (SC) Placebo-Controlled Clinical Trials and Long Term Extension Trials (2014) (14)
The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. (2019) (14)
Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al (2019) (14)
The CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses (2022) (13)
Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology (2017) (13)
Chapter 2 Epidemiology of the Antiphospholipid Syndrome (2009) (13)
Antenatal detection of intrauterine growth restriction in patients with systemic lupus erythematosus (2000) (13)
Treatment of the antiphospholipid antibody syndrome: Progress in the last five years? (2000) (13)
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach (2020) (13)
Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort (2019) (13)
Antiphospholipid antibodies: Lupus anticoagulant and anticardiolipin antibody (1992) (12)
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies (2021) (12)
Association of the BANK 1 R61H variant with systemic lupus erythematosus in Americans of European and African ancestry (2008) (12)
The clinical and serological associations of hypocomplementemia in a longitudinal sle cohort. (2020) (12)
Significance of Lipid-Derived Reactive Aldehyde-Specific Immune Complexes in Systemic Lupus Erythematosus (2016) (12)
1998 update on antiphospholipid antibodies. (1998) (12)
Genetic associations of LYN with systemic lupus erythematosus (2010) (12)
Urine Proteomics and Renal Single‐Cell Transcriptomics Implicate Interleukin‐16 in Lupus Nephritis (2021) (12)
Enhancer RNA and NF&kgr;B‐dependent P300 regulation of ADAMDEC1 (2018) (12)
OP0187 Hydroxychloroquine Blood Levels in Sle: Clarifying Dosing Controversies and Improving Adherence (2015) (12)
Risk of Renal Failure within Ten or Twenty Years of SLE Diagnosis. (2020) (11)
New classification criteria for systemic lupus erythematosus (2020) (11)
Lupus Cohort the Hopkins − − systemic lupus erythematosus risk of developing organ damage over time in Effect of corticosteroid use by dose on the (2015) (11)
Performance Characteristics of Commercial Immunoassays for the Detection of IgG and IgM Antibodies to β2 Glycoprotein I and an Initial Assessment of Newly Developed Reference Materials for Assay Calibration. (2016) (11)
Predictors of Osteonecrosis in Systemic Lupus Erythematosus: A Prospective Cohort Study (2020) (11)
Angiogenic Factor Imbalance Early in Pregnancy Predicts Adverse Outcomes in Patients With Lupus and Antiphospholipid Antibodies: Results of the PROMISSE Study (2016) (11)
Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort (2018) (11)
Evidence-based management of thrombosis in the antiphospholipid antibody syndrome (2003) (11)
Antiphospholipid Patterns Predict Risk of Thrombosis in Systemic Lupus Erythematosus. (2020) (11)
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. (2020) (11)
Clinical features of systemic lupus erythematosus. (1993) (11)
Clinical Application of a Modular Genomics Technique in Systemic Lupus Erythematosus: Progress towards Precision Medicine (2016) (11)
The immune cell landscape in kidneys of lupus nephritis patients (2018) (11)
Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies (2014) (10)
Acquired factor XIII deficiency with chronic myelomonocytic leukemia. (1983) (10)
Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort (2020) (10)
Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. (2015) (10)
Belimumab for systemic lupus erythematosus – Author's reply (2011) (10)
Accuracy of creatinine clearance in measuring glomerular filtration rate in patients with systemic lupus erythematosus without clinical evidence of renal disease. (1990) (10)
MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study (2019) (10)
Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis (2019) (10)
Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. (2021) (10)
Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry (2013) (10)
Risk factors for hypercreatinemia in patients with systemic lupus erythematosus (1999) (9)
CARDIOVASCULAR SYSTEMIC LUPUS ERYTHEMATOSUS (2004) (9)
IL-1 Transcriptional Responses to Lipopolysaccharides Are Regulated by a Complex of RNA Binding Proteins (2020) (9)
Cutaneous vasculitis in SLE (2020) (9)
A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus (2019) (9)
High-risk coronary plaque in SLE: low-attenuation non-calcified coronary plaque and positive remodelling index (2020) (9)
Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria (2021) (9)
Prevention and management of comorbidities in SLE (2014) (9)
Changes in Antiphospholipid Antibody Titers during Pregnancy: Data from the PROMISSE Study (2016) (9)
A Comparison of 2019 EULAR/ACR SLE Classification Criteria with Two Sets of Earlier SLE Classification Criteria. (2020) (9)
Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis (2020) (9)
Neonatal lupus erythematosus syndrome: analysis of C4 allotypes and C4 genes in 18 families. (1992) (9)
Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository (2020) (9)
Erratum: Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus (Immunity (2018) 49(4) (725–739.e6), (S1074761318303789), (10.1016/j.immuni.2018.08.015)) (2020) (8)
The DNA sensors AIM2 and IFI16 are SLE autoantigens that bind neutrophil extracellular traps (2022) (8)
Measures of Fatigue in Patients With Rheumatic Diseases: A Critical Review (2020) (8)
Systemic Lupus Erythematosus (SLE) (2003) (8)
Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications. (2020) (8)
The SLE-key test serological signature: new insights into the course of lupus (2018) (8)
Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice (2011) (8)
Vitamin D in SLE: Modest Association with Disease Activity and Urine Protein/Creatinine Ratio (2013) (8)
Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin (2018) (8)
RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES (2021) (8)
Tissue factor activity in patients with systemic lupus erythematosus: association with disease activity. (2000) (8)
Chronic active hepatitis presenting with rheumatoid nodules an arthritis (1987) (8)
Systemic Lupus Erythematosus and Related Diseases: Clinical Features (2006) (7)
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort (2022) (7)
Lupus nephritis outcomes: health maintenance organizations compared to non-health maintenance organizations. (2000) (7)
Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2022) (7)
Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus (2022) (7)
Hereditary resistance to activated protein C: an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies. (1997) (7)
Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases (2021) (7)
Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids (2018) (7)
Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. (2019) (7)
Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository (2019) (7)
Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation (2017) (7)
Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study (2022) (7)
Endogenous thrombin potential in the assessment of hypercoagulability in systemic lupus erythematosus (2009) (7)
OP0092 Remission in Sle: Consensus Findings from a Large International Panel on Definitions of Remission in SLE (DORIS) (2015) (7)
FRI0293 Validation of the revised selena flare index in systemic lupus erythematosus (2013) (7)
Semiquantified Noncalcified Coronary Plaque in Systemic Lupus Erythematosus (2012) (6)
A polymorphism within interleukin-21 receptor (IL21R) confers risk for systemic lupus erythematosus and is associated with malar rash in lupus patients (49.17) (2009) (6)
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network (2021) (6)
Belimumab Pregnancy Registry: Prospective Cohort Study of Pregnancy Outcomes (2014) (6)
Loss of antiphospholipid antibody positivity post-thrombosis in SLE (2020) (6)
Plasma thrombomodulin levels in women with systemic lupus erythematosus. (1995) (6)
Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index (2020) (6)
Soluble CD154 is not associated with atherosclerosis in systemic lupus erythematosus. (2007) (6)
NON-INVASIVE RENAL PROTEIN BIOMARKERS ARE ASSOCIATED WITH HISTOLOGICAL FEATURES OF LUPUS NEPHRITIS (2012) (6)
Preconceptional Cardiovascular Health and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (2018) (6)
Magnetic resonance imaging: a review of rheumatologic applications. (1986) (6)
Anti- ß 2 -Glycoprotein I: Prevalence, Clinical Correlations, and Importance of Persistent Positivity in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus (2006) (5)
Risk of Renal Failure Within 10 or 20 Years of Systemic Lupus Erythematosus Diagnosis (2021) (5)
Autoantibody clustering of lupus-associated pulmonary hypertension (2019) (5)
Testing strategies for diagnosing lupus anticoagulant: Decision analysis (2002) (5)
Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy (2019) (5)
Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection (2021) (5)
Baseline characteristics of a multiethnic lupus cohort: PROFILE (2002) (5)
THU0360 Application of New Definitions of Remission in SLE: Durable Remission Is Rare (2016) (5)
Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre (2021) (5)
Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository (2022) (5)
SAT0222 Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, particularly in antiphospholipid positive patients (2013) (5)
A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients (2017) (5)
Cardiovascular Morbidity in the Hopkins Lupus Cohort1 (2001) (5)
A TNFR2 3′ flanking region polymorphism in systemic lupus erythematosus (2000) (5)
Postmenopausal estrogen replacement therapy and risk of developing systemic lupus erythematosus or discoid lupus. (1999) (5)
Recommendations for exogenous estrogen to prevent glucocorticoid-induced osteoporosis in premenopausal women with oligo- or amenorrhea: comment on the American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. (1997) (5)
185 Baricitinib-associated changes in type I interferon gene signature during a 24-week phase 2 clinical SLE trial (2019) (5)
Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort (2021) (5)
Antiphospholipid antibody syndrome: an acquired cause of venous and arterial hypercoagulability. (1997) (4)
Low Level of Haptoglobin in Lupus (2017) (4)
' Non-criteria ' aPL tests : report of a task force and preconference workshop at the 13 th International (2011) (4)
Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus (2020) (4)
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients (2016) (4)
Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. (2019) (4)
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (‘Registry’) (2022) (4)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) (2023) (4)
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data (2021) (4)
Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression (2022) (4)
Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus (2020) (4)
Author Correction: Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities (2020) (4)
Association of African-American ethnicity and smoking status with total and individual damage index in systemic lupus erythematosus (2019) (4)
SLE-key (R) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP (R) (4)
A6.44 Only BAFF mRNA, not BAFF protein level in blood, is associated with SLE activity over one year (2015) (4)
Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus (2020) (4)
Clinical Aspects of the Antiphospholipid Syndrome (2013) (4)
Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery (2019) (4)
Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic. (2019) (4)
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update (2021) (4)
Evaluating the Construct of Damage in Systemic Lupus Erythematosus (2021) (4)
Editorial: Oral contraceptives in systemic lupus erythematosus: the case for (and against) (2008) (4)
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort (2022) (3)
Pauci-immune Glomerulonephritis in Systemic Lupus Erythematosus (SLE) (2018) (3)
Antibodies to interferon-inducible protein-16 in primary Sjögren's syndrome are associated with markers of more severe diseas (2016) (3)
Measuring disease activity and severity in clinical trials and the clinic: same or different? (2013) (3)
Clinical Outcomes Observed among Biopsy Proven Lupus Nephritis Patients Treated with Mycophenolate Mofetil as First-line Therapy (2017) (3)
Cachexia in Systemic Lupus Erythematosus: Risk Factors and Relation to Disease Activity and Damage (2020) (3)
Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset (2021) (3)
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications (2021) (3)
Classical complement activation on human erythrocytes in subjects with systemic lupus erythematosus and a history of autoimmune hemolytic anemia (2020) (3)
Cerebral Venous Thrombosis Mimicking a Discrete Brain Mass: A Case Report and Literature Review (2018) (3)
Autoantibodies targeting LINE-1-encoded ORF1p are associated with systemic lupus erythematosus diagnosis but not disease activity. (2021) (3)
THU0271 Favorable Clinical Response to Belimumab at Three Months (2013) (3)
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports (2022) (3)
Biologics use in sle in 23 centers – data from the international registry for biologics in SLE (2011) (3)
“Subcortical” cognitive impairment in patients with systemic lupus erythematosus (2000) (3)
Lupus and pregnancy: consensus and controversies. (1995) (3)
Chronic active hepatitis presenting with rheumatoid nodules and arthritis. (1987) (3)
Predictors of the start of declining eGFR in patients with systemic lupus erythematosus (2020) (3)
Antiphospholipid antibodies hasten atheroma (1996) (3)
Distinct Disease Subset Secondary Sjögren ' s Syndrome in Systemic Lupus Erythematosus Defines a (2010) (3)
Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis (2019) (3)
Gender-Based Differences in Autoimmunity and Autoimmune Disease (1995) (3)
OP0183 Hypocomplementemia Associates with Thrombosis in SLE Patients with Antiphospholipid Antibodies (2016) (2)
Pulmonary hypertension in systemic lupus erythematosus (I: Reply) (1990) (2)
Life-Threatening Complications of Systemic Lupus Erythematosus (2011) (2)
OP0045 DELINEATION OF A PROINFLAMMATORY CYTOKINE PROFILE TARGETED BY JAK1/2 INHIBITION USING BARICITINIB IN A PHASE 2 SLE TRIAL (2020) (2)
Transcription Factor Activity Inference in Systemic Lupus Erythematosus (2021) (2)
THU0304 Adherence To Hydroxychloroquine as Assessed by Measurements of Drug and Metabolite Blood Levels in An International Prospective Study of Sle Patients in Flare (2016) (2)
Intracellular homocysteine metabolites in SLE: plasma S-adenosylhomocysteine correlates with coronary plaque burden (2021) (2)
OP0160 HYDROXYCHLOROQUINE BLOOD LEVELS AND RISK OF THROMBOTIC EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS (2020) (2)
Salivary anti-nuclear antibody (ANA) mirrors serum ANA in systemic lupus erythematosus (2022) (2)
Comprehensive Urinomic Identification of Protein Alternatives to Creatinine Normalization for Diagnostic Assessment of Lupus Nephritis (2022) (2)
OP0185 Significant Clinical Improvement and Reduction of Severe Flares Following Administration of an IL-6 Monoclonal Antibody in Systemic Lupus Erythematosus (SLE) Subjects with High Disease Activity (2015) (2)
199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study (2019) (2)
OP0263 HYDROXYCHLOROQUINE DOSING IN PATIENTS WITH RHEUMATIC DISEASE ACROSS THE U.S.: DATA FROM THE RHEUMATOLOGY INFORMATICS SYSTEM FOR EFFECTIVENESS (RISE) REGISTRY (2019) (2)
Aberrant regulation of the integrin very late antigen-4 in systemic lupus erythematosus (2013) (2)
THU0387 Effects of Blisibimod, An Inhibitor of B Cell Activating Factor, On Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus (2015) (2)
OP0019 Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebo-controlled study (2018) (2)
FRI0656 ENVIRONMENTAL AND ATMOSPHERIC FACTORS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A REGRESSION ANALYSIS (2019) (2)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) (2023) (2)
139. Disease flares during pregnancy and postpartum in patients with systemic lupus erythematosus (2018) (2)
Nonlymphoma hematological malignancies in systemic lupus erythematosus (2012) (2)
Anti‐retinoblastoma Protein Antibodies: A New Specificity in Systemic Lupus Erythematosus Associated With Protection Against Lupus Nephritis (2019) (2)
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus (2022) (2)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus (2017) (2)
Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al (2013) (2)
Systemic Lupus Erythematosus: Clinical Updates in Women's Health Care Primary and Preventive Care Review. (2020) (2)
Trajectory of Damage Accrual in Systemic Lupus Erythematosus Based on Ethnicity and Socioeconomic Factors (2022) (2)
O1 Hydroxychloroquine blood levels and risk of thrombotic events in systemic lupus erythematous (2020) (2)
OP0232 Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythematosus (SLE) therapy (SOC) in patients with SLE (2017) (2)
FRI0295 Urinary tweak predicts renal disease activity in patients with systemic lupus erythematosus over a 1 year period (2013) (2)
Klinefelter’s Syndrome, 47,XXY, in Male Systemic Lupus Erythematosus Supports a Gene Dose Effect from the X Chromosome (2011) (2)
Neutralizing anti-DNase1L3 antibodies derive from autoreactive VH4-34+ B cells and associate with the interferon signature in SLE (2021) (2)
The polymorphic CYP17 allele is not found with increased frequency in systemic lupus erythematosus. (1998) (2)
Treatment Patterns and Clinical Characteristics of Patients with Systemic Lupus Erythematosus and Musculoskeletal Symptoms: A Retrospective, Observational Study (2022) (2)
Rheumatoid Pachymeningitis: A Rare Complication of Rheumatoid Arthritis (2018) (2)
The egg and I: preserving fertility in systemic lupus erythematosus (2000) (2)
The Fc gamma RIIIA-158F is a risk factor for systemic lupus erythematosus. (1997) (2)
THU0283 Two Year Follow-Up on Biologics Use in 13 Centers - Data from the International Registry for Biologics in SLE (IRBIS) (2013) (1)
THU0490 Multicentre study of lupus nephritis urinary biomarkers in adult and paediatric patients (2017) (1)
Integration of urine proteomics and renal single-cell genomics identifies an interferon-gamma response gradient in lupus nephritis. (2020) (1)
Homocysteine and vascular disease in the autoimmune connective tissue diseases (2001) (1)
Abstracts of the 16th Asia Pacific League of Associations for Rheumatology Congress, 31 March-4 April 2014, Cebu City, Philippines. (2014) (1)
One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria (2022) (1)
Lung cancer in systemic lupus erythematosus (2012) (1)
CE-01 Remission in systemic lupus erythematosus – durable remission is rare (2016) (1)
High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. (2022) (1)
SAT0385 Disease Activity Patterns Over Time in Patients with SLE – a Retrospective Descriptive Analysis of the Hopkins Lupus Cohort (2015) (1)
Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus (2022) (1)
AB0461 Benefits of vitamin d in sle depend on the organ system (2017) (1)
Systemic lupus Erythematosus and geomagnetic disturbances: a time series analysis (2021) (1)
Affinity maturation generates pathogenic antibodies with dual reactivity to DNase1L3 and dsDNA in systemic lupus erythematosus (2023) (1)
THU0212 BARICITINIB-ASSOCIATED CHANGES IN GLOBAL GENE EXPRESSION DURING A 24-WEEK PHASE 2 CLINICAL SLE TRIAL DESCRIBE A MECHANISM OF ACTION THROUGH INHIBITION OF JAK/STAT AND IFN RESPONSIVE GENE EXPRESSION (2019) (1)
Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function (2022) (1)
Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply. (2014) (1)
The association of lupus nephritis with adverse pregnancy outcomes among women with lupus in North America (2022) (1)
FRI0353 A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using A Multistate Markov Model Approach (2016) (1)
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study (2017) (1)
Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients (2013) (1)
Predictors of Seizures in Systemic Lupus Erythematosus. (2011) (1)
CS-03 Hydroxychloroquine in lupus pregnancy: a meta-analysis of individual participant data (2018) (1)
Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository (2021) (1)
Reply to "More steps forward to optimize the dosing of hydroxychloroquine". (2021) (1)
140 Effect of lupus nephritis on pregnancy outcomes in systemic lupus erythematosus: an individual participant meta-analysis (2019) (1)
Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic (2022) (1)
Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis (2022) (1)
Clinical response to belimumab in academic clinical practices (2014) (1)
Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry (2022) (1)
Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis (2015) (1)
Endocrine Manifestations in the Antiphospholipid Syndrome (2002) (1)
Lymphoma risk in systemic lupus: effects of treatment versus disease activity (2012) (1)
Clinical and histopathological features of myositis in systemic lupus erythematosus (2022) (1)
FRI0336 Hypocomplementemia in Systemic Lupus Erythematosus; Establishing The Importance of Low C3 and C4 in A Longitudinal Cohort (2016) (1)
Response to: ‘Remission in SLE: the duration depends on multiple factors, including the definition’ by Doria et al (2016) (1)
Fluctuation of Anti-Domain 1 and Anti-Β2 Glycoprotein I Antibody Titers Over Time in Patients with Persistently Positive Antiphospholipid Antibodies. (2023) (1)
Gestational weight gain in women with systemic lupus erythematosus (2017) (1)
Management of the pregnant lupus patient. (1991) (1)
History of Proliferative Glomerulonephritis Predicts End Stage Kidney Disease in Pure Membranous Lupus Nephritis. (2021) (1)
Anti-Dense Fine Speckled 70 Autoantibodies in Systemic Lupus 1 The Prevalence and Determinants of Anti-DFS 70 Autoantibodies in an International Inception Cohort of Systemic Lupus Erythematosus Patients Running Head : Anti-Dense Fine Speckled 70 Autoantibodies in SLE 1 (2018) (1)
THU0277 Epratuzumab: Sustained Safety Profile and Effect on Corticosteroid Use on Long-Term Treatment in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from an Open-Label Long-Term Extension Study (Sl0008) (2013) (1)
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. (2021) (1)
Cancer Risk Factors in SLE: Multivariate Regression Analysis in 16,409 Patients (2014) (1)
FRI0423 Impact of Disease Activity on Organ Damage Risk Over Time in Systemic Lupus Erythematosus – The Hopkins Lupus Cohort (2015) (1)
Two new murine monoclonal antibodies rised against human IgG (2001) (1)
Systemic lupus erythematosus (SLE) in pregnancy (2012) (1)
Value of Isolated IgA anti-β2GPI Positivity in the Diagnosis of the Antiphospholipid Syndrome (2014) (1)
FRI0388 Effects of Blisibimod on Serum Immunoglobulins and Infection Risk in Patients with Systemic Lupus Erythematosus from the Placebo-Controlled PEARL-SC and Open-Label Extension Studies (2014) (1)
1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms (2022) (1)
THU0270 Homocysteine, antiphospholipid antibodies and risk of vascular events in patients with systemic lupus erythematosus (2017) (1)
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus (2015) (0)
AB0621 The timing of urinary protein creatinine ratio normalization in patients with ln treated with mycophenolate mofetil (MMF) as their first line therapy (2013) (0)
S5D:4 Low vitamin d is associated with thrombosis in systemic lupus erythematosus (2018) (0)
Erratum: Development of a systemic lupus erythematosus cardiovascular risk equation (Lupus Science and Medicine (2019) 6 (e000346) DOI: 10.1136/lupus-2019-000346) (2020) (0)
Reply (2017) (0)
Salivary biomarkers in SLE (2018) (0)
Risk factors for preterm delivery in patients with systemic lupus erythmatosus (1997) (0)
Oral abstracts 1: SpondyloarthropathiesO1. Detecting axial spondyloarthritis amongst primary care back pain referrals (2012) (0)
Chapter 40 – Pregnancy (2007) (0)
FRI0431 Venous and Arterial Thrombosis in Sle: Differences in Natural History (2014) (0)
Breast, Ovarian and Endometrial Cancers in Women Diagnosed with SLE before Age 40 (2015) (0)
O4 Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus (2020) (0)
Reply to: Systemic Lupus, Immunosuppressives, COVID Vaccination and Antibody Response. (2023) (0)
High Dose Cyclophosphamide (HD CY) without Hematopoietic Stem Cell Transplantation (HSCT) in Refractory Severe Autoimmune Diseases: 11 Year Experience in Over 100 Patients. (2009) (0)
SP0043 Epidemiology of cardiovascular complications in systemic lupus erythematosus (2001) (0)
H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus (2016) (0)
103 Defining the lupus-associated pulmonary hypertension phenotype (2019) (0)
dubois' lupus erythematosus. fourth edition.edited by daniel j. wallace and bevra hannahs hahn. philadelphia, lea & febiger, 1993. 955 pp. illustrated. indexed. $125.00. (1993) (0)
Systemic lupus erythematosus: Preface (2000) (0)
Response to: ‘Belimumab and the measurement of fatigue’ by Mazzoni (2015) (0)
XIST is a source of TLR7 ligands underlying the sex bias in Systemic Lupus Erythematosus (2022) (0)
S15.2 Severe non-adherence to hydroxychloroquine is associated with flares, early damage, and mortality in systemic lupus erythematosus: data from 660 patients from the slicc inception cohort (2022) (0)
The Epigenome of SLE (49.26) (2009) (0)
Regulation of VLA-4 in lupus monocytes objectives (Annals of the Rheumatic Diseases (2011) 70 (A94)) (2011) (0)
CS-33 Performance of urinary HER2 as a biomarker of active proliferative lupus nephritis (2018) (0)
β-2-Glycoprotein Antibodies Activate the Alternative Pathway of Complement in Antiphospholipid Antibody Syndrome (2016) (0)
FRI0206 HYDROXYCHLOROQUINE BLOOD LEVELS PREDICT RETINOPATHY IN SLE (2019) (0)
Economic Evaluation of Damage Accrual in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort (2017) (0)
OP-BRHE130271 2071..2076 (2013) (0)
ACR Comparison of Gene Expression Profiles between Patients with Sjogren ’ s Syndrome and Systemic Lupus Erythematosus (2006) (0)
THU0177 ESR as a predictor of SLE disease activity and damage (2013) (0)
Comprar Pregnancy, An Issue of Rheumatic Disease Clinics | Michelle Petri | 9781416043669 | Saunders (2007) (0)
FRI0173 IDENTIFICATION OF RISK FACTORS FOR DEVELOPMENT OF OSTEONECROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS (2020) (0)
277 Body mass index at time of diagnosis is predictive of future disease activity in SLE (2019) (0)
Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study. (2014) (0)
IRF 1 marks activated genes in SLE and can induce target gene expression (2014) (0)
205 Single cell RNA expression in lupus nephritis comparing african-american and caucasian patients identifies differential expression of type I interferon pathway (2019) (0)
627 Effect of Immunosuppression on COVID Vaccination (2022) (0)
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. (2023) (0)
Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An APS ACTION Study. (2023) (0)
Lupus Nephritis Susceptibility Markers in PDGRFA-GSX2, SLC5A11, ID4, and HAS2-SNTB1 Regions Identified From a Meta-Analysis of Genome Wide Association Studies of Women with Systemic Lupus Erythematosus (2011) (0)
Pregnancy, An Issue of Rheumatic Disease Clinics (2007) (0)
Dr. Durcan, et al reply (2016) (0)
Anti-C1q Antibody in Systemic Lupus Erythematosus (2011) (0)
FRI0163 ANTIPHOSPHOLIPID PATTERNS PREDICT THE RISK OF THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS (2020) (0)
34 Comparison of remission and lupus low activity state as predictors of organ damage (2017) (0)
Effect of Systemic Lupus and Immunosuppressives on COVID Vaccination Antibody Response. (2023) (0)
AB0617 Characterization of SLE patients experiencing flares in epratuzumab clinical trials (2013) (0)
Response to Dr Nikpour's letter (2016) (0)
Reply (2021) (0)
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor (2017) (0)
Approach to the Management of Systemic Lupus Erythematosus (2000) (0)
Drug monitoring in systemic lupus erythematosus. (2022) (0)
Randomized Controlled Trials of Epratuzumab Reveal Clinically Meaningful Improvements in Patients with Moderate/Severe SLE Flares (2008) (0)
Running Head : Economic Evaluation of Lupus Damage in an International Inception Cohort Title : Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach (2019) (0)
Role of platelet-bound C4d (PC4d) in predicting risk of future thrombotic events in Systemic Lupus Erythematosus. (2023) (0)
CS-28 Validation of remission and lupus low disease activity stateas predictors of organ damage in SLE (2018) (0)
FRI0363 Positive remodelling index and low attenuation non-calcified coronary plaques: markers of vulnerable coronary plaques in systemic lupus? (2018) (0)
Quantitative screening of active renal SLE patients’ urine for protein biomarkers using kiloplexed glass slide arrays (2018) (0)
THU0341 Low vitamin d is associated with thrombosis in systemic lupus erythematosus (2018) (0)
Dr. Petri, et al reply (2013) (0)
Improvements in Diagnosis and Risk Assessment of Antiphospholipid Syndrome (2019) (0)
102 M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort (2022) (0)
SAT0529 Hydroxychloroquine Retinopathy: Update on Application of The 2011 Screening Guidelines in An Academic Practice (2016) (0)
15 Frequency of hydroxychloroquine retinopathy in the hopkins lupus cohort (2019) (0)
Decreased Live Births in Women with SLE (2010) (0)
SAT0203 SINGLE LAC POSITIVITY VERSUS DOUBLE AND TRIPLE POSITIVITY FOR THROMBOSIS IN SLE (2020) (0)
OP0252 NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY (2019) (0)
CE-21 The prevalence and determinants of ANTI-DFS70 antibodies in an international inception cohort of systemic lupus erythematosus (SLE) patients (2016) (0)
THU0178 Circulating free protein S levels may be linked to cardiovascular events and venous thrombosis in SLE (2013) (0)
14th International Congress on Antiphospholipid Antibodies - APLA & 4th LACA - Latin American Congress on Autoimmunity (2013) (0)
2.6 Systemic lupus erythematosus, Sjogren's and antiphospholipid syndrome – therapies (2012) (0)
Birmingham Construction of a frailty index as a novel health measure in systemic lupus erythematosus (2019) (0)
3 Use of Antibiotics and Subsequent Risk of Systemic Lupus Erythematosus : A Matched Case-Control Study (2015) (0)
version of SELENA comparison of BILAG 2004 and the flare with systemic lupus erythematosus : a An assessment of disease flare in patients (0)
Chapter 19 Estrogen in Systemic Lupus Erythematosus: Lessons from the SELENA Study (2008) (0)
Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients (2014) (0)
Different Control Populations May Lead to Different Understanding of Hydroxychloroquine Blood Levels as a Risk Factor for Retinopathy. (2020) (0)
FRI0439 Urinary Collagen Fragments Are Reduced in Lupus Nephritis Subjects with Renal Dysfunction (2014) (0)
AB0496 Corticosteroid Use across 52 Weeks of Belimumab Therapy in SLE Patients with High Disease Activity: Combined Analyses from the BLISS Trials (2014) (0)
37 Association of smoking status and total and individual damage index in systemic lupus erythematosus (2019) (0)
Clinical characteristics op patients with systemic lupus erythematosus associated with osteonecrosis (1996) (0)
Risk factors for pregnancy loss in women with lupus (2006) (0)
Wegener's granulomatosis: isolated involvement ofthetrachea andlarynx (1987) (0)
AB0538 Increased body mass index may not be a risk factor for the development of lupus nephritis (2018) (0)
Dr. Baer, et al reply (2011) (0)
The Epigenome of SLE (2009) (0)
LUPUS MYOCARDITIS: PREVALENCE AND RISK FACTORS IN A U.S. LONGITUDINAL COHORT (2023) (0)
455 Vitamin d deficiency is associated with inceased serum cholesterol among patients with systemic lupus erythematosus (2017) (0)
Response to: ‘Postpartum breastfeeding status’ by Betzold (2018) (0)
Incorrect Values for Intractable and Cluster Headaches at Enrollment Shown in Figure 1 and Incorrect Prevalence of Headache at Ten Years in Text of the Article by Hanly et al (Arthritis Rheum, November 2013) (2014) (0)
Oral Contraceptives and Autoimmune Diseases (2010) (0)
OP0214 Identification of Gene Transcripts and Proteins That Independently PREDICT SLE Disease Activity over the Next Year (2014) (0)
SAT0167 RACIAL DIFFERENCES IN THE IMPACT OF HYDROXYCHLOROQUINE ON IMMUNOLOGIC MARKERS IN SLE PATIENTS (2020) (0)
FRI0405 Prednisone Increases Both Arterial and Venous Thrombosis in SLE (2015) (0)
THU0251 ASSOCIATION OF SMOKING STATUS AND TOTAL AND INDIVIDUAL DAMAGE INDEX IN SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (0)
RENAL AND NONRENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: MEETING THE CLINICAL CHALLENGE (2008) (0)
Coronary plaque progression is greater in systemic lupus erythematosus than rheumatoid arthritis (2022) (0)
Nutritional Supplementation in Systemic Lupus Erythematosus (2008) (0)
Corrigendum (2015) (0)
9 th Annual Washington Rheumatology Alliance Conference (2015) (0)
Toward optimal health: Michelle Petri, M.D. discusses advances in lupus management in women with Jodi R. Godfrey (Contributing Editor). (2006) (0)
Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes (2023) (0)
SNPs in VKORC1 are Risk Factors for Systemic Lupus Erythematosus in Asians: Genetic risk factors for Lupus (2013) (0)
Anti-beta2 Glycoprotein I IgA in Systemic Lupus Erythematosus Versus Controls (2011) (0)
A prescription for exercise in systemic lupus erythematosus (2021) (0)
Anti-NET antibodies in antiphospholipid antibody-positive patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository. (2023) (0)
HMG‐CoA Reductase Inhibitors Do Not Ameliorate Progressive Atherogenic Changes In Human Macrophages Treated With Systemic Lupus Erythematosus Patient Plasma: Implications For Statin Use and Novel Insight Into Systemic Lupus Erythematosus (2018) (0)
THU0015 Efficacy versus Safety of Prednisone in Lupus Nephritis since 1988 (2014) (0)
PSYCHIATRIC DISORDER AND COGNITIVE IMPAIRMENT IN SLE. AUTHORS' REPLY (1995) (0)
Correction to: Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update (2021) (0)
CS-07 Economic evaluation of damage accrual in an international SLE inception cohort (2018) (0)
XIST ribonucleoproteins promote female sex-biased autoimmunity (2022) (0)
Urine proteomic insights from the belimumab in lupus nephritis trial (2022) (0)
189 Impact of disease activity on organ damage risk over time in systemic lupus erythematosus (sle) –the hopkins lupus cohort (2017) (0)
16 Hydroxychloroquine Blood Levels Predict Retinopathy in SLE (2019) (0)
CE-22 Cancer in systemic lupus erythematosus: results from the slicc inception cohort (2016) (0)
Clinical Aspects of Antiphospholipid Syndrome (2019) (0)
THU0255 Comparison of remission and lupus low activity state as predictors of organ damage (2017) (0)
FRI0312 Predictors of Incident Episodes of Proteinuria among Patients with Systemic Lupus Erythematosus (2016) (0)
SAT0197 Baseline laboratory characteristics from the combined placebo groups in the bliss trials are predictive of severe flare at 24 weeks (2013) (0)
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine (2022) (0)
CS-29 Creation of a weighted SLICC SLE classification criteria and comparison with other SLE classification criteria (2018) (0)
103 Exploratory segregation of patients upon their levels of anti- mitochondrial antibodies (AMAs) reveals associations between AMAs and disease manifestations (2022) (0)
4 Anti-retinoblastoma protein antibodies are negatively associated with lupus nephritis (2019) (0)
SAT0325 Smoking Is Associated with Future Lupus Cutaneous Activity in Prospective Analyses (2016) (0)
AB0462 Vitamin d supplementation significantly reduces cholesterol in sle (2017) (0)
PS4:73 Effect of hydroxychloroquine and prednisone treatment on antiphospholipid titers in sle (2018) (0)
Early complement components in quiescent SLE (1995) (0)
OP0289 LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT (2021) (0)
FRI0406 Small LDL-P Increases with Increased Disease Activity in SLE (2015) (0)
List of Contributors (2019) (0)
PS4:67 Losing antiphospholipid antibody positivity post thrombosis in secondary antiphospholipid syndrome (2018) (0)
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) (2022) (0)
Some Severe Manifestations of Systemic Lupus Erythematosus Can Be Managed (2013) (0)
The Journal of Rheumatology Procoagulants and osteonecrosis. (2003) (0)
OP0093 The Natural History of Thrombotic Events in Systemic Lupus Erythematosus and Associated Risk Factors (2015) (0)
274 Low attenuation non-calcified coronary plaques and positive remodeling index: markers of vulnerable coronary plaques in systemic lupus (2019) (0)
CE-10 Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort (2016) (0)
Mannose binding protein genetic polymorphisms associated with decreased protein are found more frequently in african american sle patients compared to a control population (1996) (0)
24 A molecular signature based on ifn gene signature and serology defines two populations of patients with different baseline disease activity (2017) (0)
PS4:80 Hydroxychloroquine in lupus pregnancy: a meta-analysis of individual participant data (2018) (0)
801 Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk (2021) (0)
Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus (2019) (0)
Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function (2012) (0)
Prevalence of Direct Coombs Test in Systemic Lupus Erythematosus. Clinical and Immunologic Associations (2011) (0)
AB0615 Favorable response to belimumab seen at three months (2013) (0)
1107 Immune cell heterogeneity in lupus nephritis kidneys and its relation to histopathological features: lessons from the accelerating medicines partnership (AMP) in SLE Consortium (2022) (0)
Rheumatologic Disorders in Pregnancy (2010) (0)
Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria (2022) (0)
The Frequency and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibodies in Antiphospholipid Antibody Patients with and without Lupus (2016) (0)
The immune cell landscape in kidneys of patients with lupus nephritis (2019) (0)
Anticardiopin antibodies: pathoetiologies for osteonecrosis in systemic lupus erythematosus? (1996) (0)
The DNA sensors AIM2 and IFI16 are NET-binding SLE autoantigens (2021) (0)
Task Force Report on “Non-criteria” Antiphospholipid Antibody Tests (2012) (0)
Erratum: Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing (Genes and Immunity (2009) vol. 10 (457-469) 10.1038/gene.2009.27) (2009) (0)
Reply (2020) (0)
Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort (2017) (0)
OP0045 Predictors of persistent disease activity and persistent long quiescence in systemic lupus erythematosus – results from the hopkins lupus cohort (2017) (0)
SAT0028 Pregnancy Outcomes in Systemic Lupus Erythematosus: Experiences from A Single US Academic Medical Center – Hopkins Lupus Pregnancy Cohort (2014) (0)
Sub-Setting Systemic Lupus Erythematosus by Combined Molecular Phenotypes Defines Divergent Populations in Two Phase III Randomized Trials. (2021) (0)
A Genetic Model for IRF5, Autoantibodies, and Interferon Alpha in Human Lupus Pathogenesis (2009) (0)
Correction to: Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis (2019) (0)
Reply (2021) (0)
The Hopkins Lupus Cohort: Pregnancy, hormones, and disease activity (1998) (0)
S2A:4 Validation of remission and lupus low disease activity state as predictors of organ damage in sle (2018) (0)
AB1007 The sle-key® test detects an sle serologic signature that persists over time and is independent of disease activity (2017) (0)
A Paper Patient-Based Flare Study in SLE (2015) (0)
A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM (2022) (0)
Detection of Hydroxychloroquine toxicity based on AAO 2016 Guidelines (2017) (0)
2002 Distinct intrarenal monocyte and macrophage populations differentiate into a common phagocytic state that is associated with histopathologic kidney injury in human lupus nephritis (2022) (0)
PS3:45 Spatial-time cluster analysis of sle disease activity (2018) (0)
O2 Effect of treatment on antiphospholipid antibodies in SLE (2020) (0)
Reply (2018) (0)
Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (""Registry"") (2018) (0)
Review of endocrine manifestations of antiphospholid syndrome (2010) (0)
Erratum: Genetic associations of LYN with systemic lupus erythematosus (Genes and Immunity (2009) 10 (397-403) DOI: 10.1038/gene.2009.19) (2010) (0)
SAT0428 Application of New Eular Definitions of Remission in SLE: Durable One-Year Remission is Rare (2015) (0)
The Journal of Rheumatology Lupus Erythematosus: Results from the SLICC Inception Cohort Osteopontin and Disease Activity in Patients with Recent-onset Systemic (2019) (0)
The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study (2015) (0)
Reply (2020) (0)
AI-07 A new B cell effector pathway with defective negative regulation of TLR7 signaling in human SLE (2018) (0)
603 Remission and low disease activity are associated with lower health care costs in an international inception cohort of patients with systemic lupus erythematosus (2022) (0)
A Prospective Study of Seizures in Systemic Lupus Erythematosus. (2011) (0)
FRI0381 Interferon Dysregulation in an Academic SLE Cohort is Associated with Distinct Signaling Differences in Blood Neutrophils VS. Peripheral Blood Mononuclear Cells (2015) (0)
SAT0204 Predictors for SLE flares: Baseline disease activity and demographic characteristics from the bliss trials’ combined placebo groups (2013) (0)
501 Role of platelet-bound complement activation product (PC4d) in predicting risk of future thrombotic events in systemic lupus erythematosus (2022) (0)
1401 A Genome Wide Association Scan of SLE genetic risk in a cohort of African-American persons (2022) (0)
Reply to Letter to Editor: Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. (2019) (0)
Serum chemokine levels predict flares of disease activity in two independent systemic lupus erythematosus cohorts (2012) (0)
FRI0255 LOW ATTENUATION NON-CALCIFIED CORONARY PLAQUES AND POSITIVE REMODELING INDEX: MARKERS OF VULNERABLE CORONARY PLAQUES IN SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (0)
Only IgG and IgA beta(2)glycoprotein I Antibody Isotypes Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus (2013) (0)
1704 Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes (2021) (0)
Hopkins Lupus Cohort: assessment of treatment effects (2012) (0)
28 Drivers of the sle responder index (sri-5) endpoint in clinical trials of sle (2017) (0)
Thromboembolic events in lupus patients with antiphospholipid Ab are not strongly associated with the factor V mutation of APC resistance (1995) (0)
eScholarship Title Progression of coronary artery atherosclerosis in rheumatoid arthritis : comparison with participants from the Multi-Ethnic Study of Atherosclerosis (2013) (0)
1114 Trajectory of damage accrual in systemic lupus erythematosus based on ethnicity, socioeconomic factors and comorbidities (2021) (0)
THU0369 Creation of a weighted slicc sle classification criteria and comparison with proposed eular/acr sle classification criteria (2018) (0)
FRI0182 FREQUENCY OF HYDROXYCHLOROQUINE RETINOPATHY IN THE HOPKINS LUPUS COHORT (2019) (0)
AB0486 The Complete Response in Patients with Lupus Nephritis Treated with Mycophenolate Mofetil (MMF) as Their First Line Therapy (2014) (0)
Microsporidia and Mammalian Tumors (1976) (0)
Overdiagnosis of endometrial carcinoma (1982) (0)
Diagnostic and Therapeutic Approach in Invasive Fungal Infections of Intensive Care Unit Patients (1994) (0)
297 Environmental and atmospheric factors in systemic lupus erythematosus: a regression analysis (2019) (0)
Randomized comparative trial on secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. (1990) (0)
[Randomized comparative study of secondary prevention of Pneumocystis carinii pneumonia in patients with acquired immunologic deficiency syndrome]. (1990) (0)
SAT0685 Temperature and small particulate matter pollution are associated with organ specific lupus flares: a spatio -temporal analysis (2018) (0)
[Microsporidiosis. A new disease in warm blooded animals and man]. (1968) (0)
AB0167 SINGLE CELL RNA EXPRESSION IN LUPUS NEPHRITIS COMPARING AFRICAN-AMERICAN AND CAUCASIAN PATIENTS IDENTIFIES DIFFERENTIAL EXPRESSION OF TYPE I INTERFERON PATHWAY (2019) (0)
Infertility, Oral Contraceptive Pills, Hormone Replacement Therapy and the Antiphospholipid Antibody Syndrome (2000) (0)
Reply (2014) (0)
THU0339 Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus (2016) (0)
Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics (SLICC) Cohort using Multistate Modelling. (2023) (0)
POS0304 EPIDEMIOLOGY AND ECONOMIC BURDEN ASSOCIATED WITH MENTAL HEALTH COMORBIDITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS PATIENTS (2021) (0)
Corrigendum (2010) (0)
PO.1.5 Scoring personalized molecular portraits identify systemic lupus erythematosus subtypesand predict transcriptional drug responses, symptomatology and disease progression (2022) (0)
Patients and methods Patients The Hopkins Lupus (2014) (0)
OP0122 Validation of remission and lupus low disease activity state as predictors of organ damage in sle (2018) (0)
Reply to Letter to Editor: Do Hydroxychloroquine Blood Levels and Dosage Identify the Same or Different Populations at Risk for Retinopathy? (2020) (0)
FRI0387 Association of Pre-Pregnancy Body Mass Index with Preterm Birth and Birthweight Percentiles in Systemic Lupus Erythematosus (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michelle A. Petri?

Michelle A. Petri is affiliated with the following schools:

Michelle A. Petri's Academic­Influence.com Rankings

Michelle A. Petri's Degrees

Why Is Michelle A. Petri Influential?

Michelle A. Petri's Published Works

Published Works

What Schools Are Affiliated With Michelle A. Petri?

Michelle A. Petri's AcademicInfluence.com Rankings